SBFM · Sunshine Biopharma Inc.
Sunshine Biopharma Inc (SBFM)
What's happening
- SBFM is down 4.23% today, trading at $0.22. — Live quote
- It's trading within 3% of its 52-week low ($0.19). (Finnhub fundamentals)
- Volume today (6,463) is well below its 3-month average of 3,983,480. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | — | $31.1M | $54.4M |
| P/E | — | — | — | -6.70 | -13.10 |
| Price/Sales | — | — | — | 0.86 | 1.59 |
| Price/Book | — | — | — | 1.21 | 2.40 |
| EV/Revenue | — | — | — | 0.86 | 1.59 |
| ROE | — | — | — | -18.08% | -18.30% |
| ROA | — | — | — | -14.52% | -14.24% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -1.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -16.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -98.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SBFM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $9.4M | $9.4M | $8.9M | $8.4M | $9.3M | $7.5M |
| Gross profit | $2.4M | $2.2M | $3.1M | $3.4M | $2.7M | $2.9M | $2.4M | $2.4M |
| Operating income | -$1.6M | -$1.4M | -$1.1M | -$2.1M | -$1.3M | -$1.1M | -$1.3M | -$1.4M |
| Net income | -$1.6M | -$1.2M | -$883.8K | -$1.8M | -$1.2M | -$1.2M | -$494.3K | -$1.3M |
| EPS (diluted) | — | — | — | $-0.82 | $-0.44 | — | $-43.48 | $-2.00 |
| EPS (basic) | $-1.15 | $-0.25 | $-0.19 | $-3.94 | $-0.44 | $-0.94 | $-9.94 | $-2.00 |
| Operating margin | -$17 | -$17 | -$12 | -$22 | -$15 | -$13 | -$14 | -$18 |
| Net margin | -$17 | -$15 | -$9 | -$19 | -$13 | -$14 | -$5 | -$17 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $33.6M | $27.9M | $30.1M | $31.5M | $32.0M | $29.2M | $30.6M | $30.1M |
| Total liabilities | $6.1M | $6.4M | $7.0M | $7.3M | $6.3M | $6.5M | $7.1M | $5.0M |
| Stockholders' equity | $27.5M | $21.5M | $23.0M | $24.2M | $25.7M | $22.7M | $23.5M | $25.0M |
| Total current assets | $30.7M | $24.8M | $26.9M | $28.0M | $27.9M | $24.5M | $26.0M | $26.0M |
| Total current liabilities | $5.6M | $5.9M | $6.4M | $6.7M | $5.6M | $5.8M | $6.3M | $4.5M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $4.0M | $4.0M | $3.5M | $4.2M | $3.6M | $3.4M | $3.9M | $3.2M |
| Inventory | $12.1M | $13.2M | $13.5M | $14.1M | $13.0M | $11.9M | $11.3M | $9.8M |
| Property, plant & equipment | $477.0K | $516.3K | $557.4K | $598.1K | $638.4K | $519.8K | $546.1K | $590.8K |
| Goodwill | — | — | — | — | — | — | $0 | — |
| Intangible assets | $1.8M | $1.9M | $1.9M | $2.0M | $2.5M | $3.2M | $3.0M | $2.9M |
| Accounts payable | $4.9M | $5.1M | $5.7M | $6.1M | $4.8M | $5.0M | $5.5M | $4.2M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.4K | $4.9K | $491 | $4.6K | $4.6K | $2.7K | $2.6K | $2.0K |
| Retained earnings | -$77.8M | -$76.3M | -$75.0M | -$72.9M | -$72.0M | -$70.2M | -$69.0M | -$66.9M |
| Accumulated other comprehensive income (loss) | -$658.9K | -$343.3K | -$65.3K | -$320.8K | $280.8K | -$803.8K | -$830.0K | $168.6K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$918.0K | -$2.1M | -$1.6M | -$746.7K | -$1.3M | -$1.7M | -$3.4M | -$1.4M |
| Investing cash flow | -$5.1K | -$104.5K | -$50.2K | -$23.9K | -$550.2K | -$212.0K | -$97.8K | -$670.6K |
| Financing cash flow | $7.8M | $0 | $724.5K | $0 | $3.7M | $355.3K | $1.6M | $2.0M |
| Free cash flow | -$925.0K | -$2.1M | -$1.6M | -$754.7K | -$1.4M | -$1.7M | -$3.5M | -$1.9M |
| Capital expenditures | $7.0K | $5.1K | -$1.0K | $8.0K | $160.0K | $7.5K | $102.6K | $517.0K |
| Depreciation & amortization | $78.0K | $76.9K | $98.6K | $96.3K | $72.4K | $64.8K | $65.4K | $64.6K |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Deferred income taxes | — | — | $94.9K | — | — | — | -$144.5K | — |
| Change in accounts receivable | $88.6K | $609.6K | -$41.3K | $649.9K | -$65.7K | -$426.7K | $1.0M | -$987.0K |
| Change in inventory | -$794.0K | -$78.4K | -$772.8K | $1.3M | $555.1K | $568.8K | $1.8M | $1.3M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228.4K |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110.6K |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M |
| EPS (diluted) | — | $-7.32 | $-351.36 | $-1.76 | $-4.76 |
| EPS (basic) | $-1.44 | $-7.32 | $-351.36 | $-1.76 | $-4.76 |
| Operating margin | -$17 | -$17 | -$20 | -$621 | -$1.1K |
| Net margin | -$16 | -$15 | -$19 | -$615 | -$5.4K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
| Stockholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $211.7K |
| Total current assets | $26.9M | $26.0M | $24.9M | $27.3M | $2.2M |
| Total current liabilities | $6.4M | $6.3M | $5.6M | $6.9M | $91.2K |
| Cash & equivalents | — | — | — | $21.8M | $2.0M |
| Accounts receivable | $3.5M | $3.9M | $2.6M | $1.9M | $7.8K |
| Inventory | $13.5M | $11.3M | $5.7M | $3.3M | $105.7K |
| Property, plant & equipment | $557.4K | $546.1K | $365.9K | $394.2K | $7.1K |
| Goodwill | — | $0 | $0 | $0 | $0 |
| Intangible assets | $1.9M | $3.0M | $1.4M | $776.9K | $0 |
| Accounts payable | $5.7M | $5.5M | $2.6M | $2.8M | $42.9K |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $4.9K | $2.6K | $14 | $22.6K | $2.6K |
| Retained earnings | -$75.0M | -$69.0M | -$63.9M | -$59.4M | -$32.7M |
| Accumulated other comprehensive income (loss) | -$65.3K | -$830.0K | $696.1K | $161.8K | -$23.1K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Investing cash flow | -$836.3K | -$2.0M | -$656.1K | -$14.6M | $0 |
| Financing cash flow | $4.7M | $8.9M | $3.4M | $39.5M | $2.9M |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M |
| Capital expenditures | $174.5K | $1.7M | $82.3K | $194.0K | $0 |
| Depreciation & amortization | $332.1K | $223.5K | $149.1K | — | — |
| Share-based compensation | — | — | — | — | — |
| Deferred income taxes | $94.9K | -$144.5K | — | — | — |
| Change in accounts receivable | $116.2K | $2.3M | $594.1K | $524.5K | $5.9K |
| Change in inventory | $1.6M | $6.0M | $2.4M | -$43.0K | $81.9K |
| Change in accounts payable | — | — | — | — | — |
| Share repurchases | $0 | $3.1M | $541.1K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SBFM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2017-07-20 to 2026-08-07
Recent transactions
- Most recent: NATAN DAVID (Director) — Grant / award of 58,300 shares on 2026-08-07.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| NATAN DAVID | Director | Grant / award | 2026-08-07 | 58,300 |
| Slilaty Steve N. | Chief Executive Officer | Open market purchase | 2024-03-04 | 100,000 |
| Sebaaly Camille | CFO/Secretary | Open market purchase | 2022-11-30 | 30,000 |
| MERZOUKI ABDERRAZZAK | Chief Operating Officer | Grant / award | 2021-01-06 | 20,000,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-07 | NATAN DAVID | Director | Grant / award | 58,300 | $0.00 |
| 2026-04-14 | NATAN DAVID | Director | Grant / award | 100,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-11 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-20 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-07-10 | 8-K | 2026-07-08 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-28 | View on SEC.gov → |
| 2026-05-19 | 8-K | 2026-05-18 | View on SEC.gov → |
Recent news
Headlines about SBFM (Sunshine Biopharma Inc.). Links open the publisher — we don’t host full articles.
-
There are notable gap-ups and gap-downs in today's session.
ChartMill · 2026-10-15 -
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2026-10-15 -
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2026-10-13 -
These stocks are moving in today's session
ChartMill · 2026-10-09 -
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
Yahoo · 2026-10-09 -
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2026-10-09 -
Top stock movements in today's session.
ChartMill · 2026-10-08 -
These stocks are making the most noise in today's session.
ChartMill · 2026-10-08
No headlines in this category right now — try “All”.